Can Humira (adalimumab) cause elevated liver enzymes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Humira Increase Liver Enzymes?

Yes, Humira (adalimumab) can cause elevated liver enzymes, though this occurs infrequently and is usually mild and transient. According to FDA labeling data, ALT elevations ≥3 times the upper limit of normal (ULN) occurred in 3.5% of adalimumab-treated patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis compared to 1.5% of control patients 1.

Incidence and Severity

The elevation of liver enzymes with adalimumab varies by indication:

  • Rheumatoid arthritis/Psoriatic arthritis/Ankylosing spondylitis: ALT elevations ≥3x ULN in 3.5% of patients 1
  • Crohn's disease (adults): ALT elevations ≥3x ULN in 0.9% of patients 1
  • Ulcerative colitis (adults): ALT elevations ≥3x ULN in 1.5% of patients 1
  • Psoriasis: ALT elevations ≥3x ULN in 1.8% of patients 1
  • Juvenile idiopathic arthritis: ALT elevations ≥3x ULN in 4.4% of patients (more common when combined with methotrexate) 1

Most elevations are asymptomatic and do not lead to treatment discontinuation 1. However, severe hepatic reactions including acute liver failure have been reported with TNF-blockers, though these are rare 1.

Clinical Patterns

Liver injury from adalimumab can manifest in different patterns:

  • Hepatocellular injury (most common): Elevated transaminases 2, 3
  • Cholestatic injury: Elevated alkaline phosphatase and bilirubin, which is rarer but can be severe 4, 5
  • Mixed pattern: Features of both hepatocellular and cholestatic injury 2

The British Association of Dermatologists guidelines note that hepatotoxicity with TNF inhibitors like adalimumab is well recognized, with elevations generally being transient and asymptomatic, though rare cases of severe hepatitis and acute liver failure have been reported 6.

Monitoring Recommendations

Baseline and periodic monitoring of liver enzymes is essential:

  • Measure complete blood count, liver enzymes, and serum creatinine prior to initiation 7
  • Monitor every 3-6 months during ongoing therapy 7
  • More frequent monitoring if elevations occur or if concomitant hepatotoxic medications are used 1

Management Algorithm

When liver enzyme elevations occur:

  1. ALT/AST <3x ULN: Continue adalimumab with closer monitoring; recheck at shorter intervals 7

  2. ALT/AST 3-5x ULN:

    • Temporarily hold adalimumab
    • Rule out other causes (viral hepatitis, other medications, alcohol, liver metastases)
    • Consider dose reduction or temporary discontinuation 7
  3. ALT/AST >5x ULN:

    • Discontinue adalimumab
    • Investigate alternative causes thoroughly
    • Consider liver biopsy if etiology unclear or if steroid-refractory 8
  4. Signs of liver failure (jaundice, coagulopathy, encephalopathy):

    • Permanently discontinue adalimumab 1
    • Urgent hepatology consultation

Important Caveats

Concomitant medications complicate interpretation: Many patients receiving adalimumab also take methotrexate or NSAIDs, which independently cause liver enzyme elevations. The FDA label notes that "the relationship between HUMIRA and the liver enzyme elevations is not clear" in these cases 1. Liver enzyme elevations were more frequent with adalimumab plus methotrexate combination therapy than adalimumab alone 1.

Risk factors to consider: Patients with pre-existing liver disease, obesity, alcohol use, or concurrent hepatotoxic medications may be at higher risk 6. However, severe liver injury has been reported even in patients without prior liver disease or risk factors 3, 4.

Comparative data: Among TNF inhibitors, infliximab shows the highest risk of liver enzyme elevation (adjusted OR 1.58-2.40), followed by adalimumab (adjusted OR 1.35-1.72), while etanercept shows no significant increase compared to non-biologic DMARDs 9. Interestingly, recent data suggest that TNF inhibitor therapy may actually improve liver enzymes in some RA patients with baseline elevations 10.

Time course: Most cases of drug-induced liver injury from adalimumab occur within the first few months of therapy, with latency typically 1-4 months 2, 11. Improvement generally occurs within weeks to months after discontinuation 5.

References

Research

Subacute liver failure induced by adalimumab.

International journal of clinical pharmacology and therapeutics, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.